# Judge report — JNJ FY2025 memo

*Judged 2026-06-12T21:01:57+00:00 by claude-opus-4-8. Cost: $0.5518.*

| dimension | score |
|---|---|
| factual_grounding | 4/5 |
| internal_consistency | 5/5 |
| honesty | 5/5 |
| specificity | 5/5 |

## Justifications

### factual_grounding — 4/5

Most quotes verify verbatim against the filing and metrics match real values (6.0% to $94.2B, STELARA 6.2/7.6/4.4%, Oncology +22.1%, Cardiovascular +15.8%, $14.5B Intra-Cellular, OPSUMIT 2026). However, one talc attribution misquotes: memo states FY2024 charge 'became a ~$7.0 billion reserve reversal' citing prior-year text 'charges for talc matters of approximately $5.1 billion and $7.0 billion, respectively' — the $7.0B there is the FY2023 charge, not a reversal, a stitched/misread attribution. ROE 131% matches but is flagged anomalous.

- evidence: “"In 2025, worldwide sales increased 6.0% to $94.2 billion as compared to an increase of 4.3% in 2024."”
- evidence: “"charges for talc matters of approximately $5.1 billion and $7.0 billion, respectively"”

### internal_consistency — 5/5

The memo coheres: 6.0% filing growth aligns with model revenue_growth_1y ~6%; high screen rank is repeatedly reconciled against forward pricing/exclusivity headwinds; moderate confidence is justified with explicit tension between rank and outlook. The memo also self-discloses traceability warnings rather than hiding them, and the score is consistently framed as ranked-screen not probability.

- evidence: “"this is a relative prioritization signal, not a forecast"”
- evidence: “"creating modest tension between the high screen rank and the qualitative outlook"”

### honesty — 5/5

Strong respect for limitations: repeatedly states the score is a ranked screen not a calibrated classifier, flags survivorship bias, ex-Financials universe, filing-date-only information, and the anomalous ROE. Explicitly declares data gaps (Notes 7/8/19 unavailable) and surfaces its own traceability warnings. No material overclaiming detected.

- evidence: “"It is NOT a calibrated classifier... Scores order companies by relative likelihood of revenue growth; they are not probabilities to act on."”
- evidence: “"All inputs are information available at the 10-K filing date only"”

### specificity — 5/5

Every key point is JNJ-specific and grounded: named products (STELARA, DARZALEX, CARVYKTI, OPSUMIT, CAPLYTA), exact figures, the Orthopaedics separation, $14.5B Intra-Cellular, talc reserve movement, IRA/Part D, MedTech tariffs. No generic large-cap filler.

- evidence: “"Oncology sales grew 22.1% to $25.4 billion, led by DARZALEX share gains... CARVYKTI capacity expansion"”
- evidence: “"the planned Orthopaedics separation (targeted within 18-24 months of the October 2025 announcement)"”

## Defects found

- Talc attribution conflates prior-year '$5.1B and $7.0B' charges (FY2024/FY2023) with the FY2025 $7.0B reversal claim — stitched/misread source
- Talc reserve figures (~$11.6B to ~$3.4B) draw on Notes the memo admits were not provided, partly unverifiable from given sections
- Three findings carry self-flagged traceability warnings where attributions weren't found in the cited agent output
- ROE ~131% cited though acknowledged as anomalous/artifact

## Verdict

A high-quality, specific, and honest memo well grounded in the filing with consistent framing of the model signal as a ranked screen. The principal defect is a misattributed talc quote where the FY2023 $7.0B charge is conflated with the FY2025 reversal narrative; the memo's own traceability warnings flag this attribution as unverified.

## Sources provided to the judge

- EDGAR_X.RAW.RAW_FILINGS accession 0000200406-26-000016 (10-K filed 2026-02-11, fields mdna_text / risk_factors_text)
- EDGAR_X.RAW.RAW_FILINGS accession 0000200406-25-000038 (10-K filed 2025-02-13, fields mdna_text / risk_factors_text)
- EDGAR_X.INTERMEDIATE.INT_ML_FEATURES (ticker=JNJ, fiscal_year=2025)
- XGBoost revenue-direction model (xgboost_revenue_direction.json) scored on the FY2025 feature row from EDGAR_X.INTERMEDIATE.INT_ML_FEATURES
